GB201421716D0 - Cell expansion procedure - Google Patents

Cell expansion procedure

Info

Publication number
GB201421716D0
GB201421716D0 GBGB1421716.0A GB201421716A GB201421716D0 GB 201421716 D0 GB201421716 D0 GB 201421716D0 GB 201421716 A GB201421716 A GB 201421716A GB 201421716 D0 GB201421716 D0 GB 201421716D0
Authority
GB
United Kingdom
Prior art keywords
cell expansion
expansion procedure
procedure
cell
expansion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1421716.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kings College London
Original Assignee
Kings College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kings College London filed Critical Kings College London
Priority to GBGB1421716.0A priority Critical patent/GB201421716D0/en
Publication of GB201421716D0 publication Critical patent/GB201421716D0/en
Priority to EP20152991.4A priority patent/EP3696263A1/en
Priority to DK15819849.9T priority patent/DK3227435T3/da
Priority to CA2969783A priority patent/CA2969783C/en
Priority to CN201580072217.6A priority patent/CN107208061B/zh
Priority to MX2017007214A priority patent/MX392057B/es
Priority to EP15819849.9A priority patent/EP3227435B1/en
Priority to RU2017121191A priority patent/RU2017121191A/ru
Priority to AU2015356788A priority patent/AU2015356788B2/en
Priority to US15/532,921 priority patent/US10557117B2/en
Priority to PCT/GB2015/053713 priority patent/WO2016087871A1/en
Priority to JP2017529381A priority patent/JP6802159B2/ja
Priority to KR1020177018323A priority patent/KR102686005B1/ko
Priority to ZA2017/04499A priority patent/ZA201704499B/en
Priority to US16/719,650 priority patent/US11566222B2/en
Priority to US16/719,625 priority patent/US20200140816A1/en
Priority to US18/158,146 priority patent/US20230323298A1/en
Priority to US18/964,041 priority patent/US20250092364A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/42—Organic phosphate, e.g. beta glycerophosphate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB1421716.0A 2014-12-05 2014-12-05 Cell expansion procedure Ceased GB201421716D0 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
GBGB1421716.0A GB201421716D0 (en) 2014-12-05 2014-12-05 Cell expansion procedure
KR1020177018323A KR102686005B1 (ko) 2014-12-05 2015-12-04 감마델타 t 세포 증식 절차
AU2015356788A AU2015356788B2 (en) 2014-12-05 2015-12-04 Gammadelta T cell expansion procedure
PCT/GB2015/053713 WO2016087871A1 (en) 2014-12-05 2015-12-04 Gammadelta t cell expansion procedure
CA2969783A CA2969783C (en) 2014-12-05 2015-12-04 Gammadelta t cell expansion procedure
CN201580072217.6A CN107208061B (zh) 2014-12-05 2015-12-04 γδ T细胞扩增方法
MX2017007214A MX392057B (es) 2014-12-05 2015-12-04 Procedimiento para la expansion de linfocitos t gamma/delta.
EP15819849.9A EP3227435B1 (en) 2014-12-05 2015-12-04 Gammadelta t cell expansion procedure
RU2017121191A RU2017121191A (ru) 2014-12-05 2015-12-04 Методика размножения гамма-дельта Т-клеток
EP20152991.4A EP3696263A1 (en) 2014-12-05 2015-12-04 Gammadelta t cell expansion procedure
US15/532,921 US10557117B2 (en) 2014-12-05 2015-12-04 Gammadelta T cell expansion procedure
DK15819849.9T DK3227435T3 (da) 2014-12-05 2015-12-04 Gammadelta-t-celleekspansionsprocedure
JP2017529381A JP6802159B2 (ja) 2014-12-05 2015-12-04 ガンマデルタｔ細胞増殖手順
ZA2017/04499A ZA201704499B (en) 2014-12-05 2017-07-03 Gammadelta t cell expansion procedure
US16/719,650 US11566222B2 (en) 2014-12-05 2019-12-18 γδ T cell expansion procedure
US16/719,625 US20200140816A1 (en) 2014-12-05 2019-12-18 Gammadelta t cell expansion procedure
US18/158,146 US20230323298A1 (en) 2014-12-05 2023-01-23 Gammadelta t cell expansion procedure
US18/964,041 US20250092364A1 (en) 2014-12-05 2024-11-29 Gammadelta T Cell Expansion Procedure

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1421716.0A GB201421716D0 (en) 2014-12-05 2014-12-05 Cell expansion procedure

Publications (1)

Publication Number Publication Date
GB201421716D0 true GB201421716D0 (en) 2015-01-21

Family

ID=52425560

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1421716.0A Ceased GB201421716D0 (en) 2014-12-05 2014-12-05 Cell expansion procedure

Country Status (13)

Country Link
US (5) US10557117B2 (https=)
EP (2) EP3696263A1 (https=)
JP (1) JP6802159B2 (https=)
KR (1) KR102686005B1 (https=)
CN (1) CN107208061B (https=)
AU (1) AU2015356788B2 (https=)
CA (1) CA2969783C (https=)
DK (1) DK3227435T3 (https=)
GB (1) GB201421716D0 (https=)
MX (1) MX392057B (https=)
RU (1) RU2017121191A (https=)
WO (1) WO2016087871A1 (https=)
ZA (1) ZA201704499B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201421716D0 (en) 2014-12-05 2015-01-21 King S College London Cell expansion procedure
KR102032354B1 (ko) * 2016-11-11 2019-10-16 가톨릭대학교 산학협력단 신규한 배양보조세포 및 이를 이용한 감마 델타 ｔ 세포의 증식 방법
DE102017127984B4 (de) 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
CN108588023B (zh) 2018-05-09 2020-02-14 河北森朗生物科技有限公司 一种生产嵌合抗原受体修饰的γδT细胞的方法
TW202020145A (zh) 2018-07-13 2020-06-01 國立大學法人京都大學 γδＴ細胞的製造方法
CA3114292A1 (en) * 2018-09-27 2020-04-02 Phosphogam, Inc. Methods and compositions for the expansion and use of allogeneic gamma/delta-t cells
CN109234236A (zh) * 2018-09-29 2019-01-18 吉林大学第医院 一种嵌合抗原受体γδT细胞的制备方法
SG11202104692VA (en) * 2018-11-08 2021-06-29 In8Bio Inc Compositions and methods for treating cancer
CN110184240B (zh) * 2019-06-13 2020-11-20 上海市肺科医院 一种高效扩增活化Vγ2Vδ2 T细胞增强其抗结核活性的方法
CA3162755A1 (en) 2019-11-25 2021-06-03 Kyoto University T-cell master cell bank
US11999968B2 (en) 2021-10-22 2024-06-04 Fullhope Biomedical Co., Ltd Modified T cells, pharmaceutical composition, manufacturing method thereof, and method of using the same
KR20230105166A (ko) * 2022-01-03 2023-07-11 주식회사 이뮤노맥스 감마-델타 t 세포의 증식 배양 방법
CN114645022B (zh) * 2022-05-13 2022-09-02 首都医科大学宣武医院 靶向CD5的CAR-γ δ T细胞及其制备方法与应用
JP2025064863A (ja) * 2023-10-06 2025-04-17 株式会社マイオリッジ Ｔ細胞の培養方法
JP7725011B1 (ja) * 2024-02-01 2025-08-19 ミヤリサン製薬株式会社 Ｃｄ４－ｃｄ８－ｔ細胞を増殖および／または活性化させるための組成物
CN120924492B (zh) * 2025-10-15 2026-03-03 瑞因细胞工程科技(广州)有限公司 一种脐血来源γδT细胞的体外诱导组合物及培养方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7256498A (en) 1997-04-25 1998-11-24 Wistar Institute Of Anatomy And Biology, The Cytolytic t-cell clones against colorectal carcinoma and methods of use thereof
AU747767B2 (en) * 1997-11-05 2002-05-23 University Of Southern California Use of cytokines and mitogens to inhibit pathological immune responses
ATE421573T1 (de) * 1998-11-04 2009-02-15 Therapure Biopharma Inc Verfahren zur herstellung von gamma delta t zellen
US20030157060A1 (en) * 2000-04-03 2003-08-21 Bell David N Production of tcr gamma delta t cells
FR2836483B1 (fr) 2002-02-22 2006-09-15 Innate Pharma Procedes de production de lymphocytes gamma delta t
EP1426052B1 (en) 2002-12-02 2009-09-02 Innate Pharma Compositions comprising interleukin-2 and gamma-delta T cell activator and uses thereof
EP1720567A2 (en) 2004-02-10 2006-11-15 Innate Pharma Composition and method for the treatment of carcinoma
WO2006006720A1 (ja) * 2004-07-13 2006-01-19 Medinet., Co.Ltd γδＴ細胞の培養方法、γδＴ細胞及び治療・予防剤
DE602005022728D1 (de) * 2004-08-19 2010-09-16 Univ Cardiff Präparation antigenpräsentierender menschlicher gamma delta t-zellen und verwendung in der immuntherapie
AU2006272647A1 (en) 2005-07-25 2007-02-01 Therimunex Pharmaceuticals, Inc. Peptidyl diacylglycerides
WO2008059052A1 (en) * 2006-11-17 2008-05-22 Innate Pharma Improved methods of using phosphoantigen for the treatment of cancer
WO2008129874A1 (ja) * 2007-04-13 2008-10-30 Medinet Co., Ltd. 腫瘍細胞の標的化方法、及びその用途
ITRM20070437A1 (it) * 2007-08-10 2009-02-11 Istituto Naz Per Le Malattie I Metodo per la generazione ed espansione di cellule t gamma/delta regolatorie cellule cosi' ottenute e loro impieghi
WO2009131730A2 (en) 2008-01-31 2009-10-29 University Of Iowa Research Foundation IMMUNOGENIC COMPOSITIONS FOR ACTIVATING γδ T CELLS
US8962313B2 (en) * 2008-07-01 2015-02-24 Medinet Co., Ltd. Method for the simultaneous induction of CTL and γδT cell
US8828944B2 (en) 2010-04-22 2014-09-09 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
WO2012131419A1 (en) * 2011-03-25 2012-10-04 Txcell Method for using regulatory t cells in therapy
US10584158B2 (en) 2013-04-17 2020-03-10 Baylor College Of Medicine Immunosuppressive TGF-β signal converter
CN103436492B (zh) * 2013-08-02 2016-03-02 北京赛诺泰生物科技有限公司 通过无血清培养扩增活化淋巴细胞的方法
CN103436493B (zh) * 2013-08-29 2016-02-03 浙江大学 雷帕霉素诱导调节性γδT细胞的培养方法
GB201421716D0 (en) 2014-12-05 2015-01-21 King S College London Cell expansion procedure

Also Published As

Publication number Publication date
EP3696263A1 (en) 2020-08-19
RU2017121191A3 (https=) 2019-07-29
AU2015356788A1 (en) 2017-07-13
US11566222B2 (en) 2023-01-31
CA2969783C (en) 2023-08-01
CA2969783A1 (en) 2016-06-09
MX392057B (es) 2025-03-21
US20200123502A1 (en) 2020-04-23
US10557117B2 (en) 2020-02-11
ZA201704499B (en) 2019-09-25
US20170342381A1 (en) 2017-11-30
RU2017121191A (ru) 2019-01-10
US20230323298A1 (en) 2023-10-12
CN107208061B (zh) 2025-11-18
AU2015356788B2 (en) 2021-09-30
KR20170084337A (ko) 2017-07-19
US20200140816A1 (en) 2020-05-07
US20250092364A1 (en) 2025-03-20
JP2017537625A (ja) 2017-12-21
CN107208061A (zh) 2017-09-26
WO2016087871A1 (en) 2016-06-09
MX2017007214A (es) 2018-01-30
EP3227435B1 (en) 2020-01-29
KR102686005B1 (ko) 2024-07-17
JP6802159B2 (ja) 2020-12-16
EP3227435A1 (en) 2017-10-11
DK3227435T3 (da) 2020-05-04

Similar Documents

Publication Publication Date Title
IL274903A (en) cell
ZA201707334B (en) Cell
GB201507368D0 (en) Cell
GB201503500D0 (en) Cell
GB201514874D0 (en) Cell
GB201518817D0 (en) Cell
GB201610515D0 (en) Cell
GB201421716D0 (en) Cell expansion procedure
GB201522097D0 (en) Cells
GB201621889D0 (en) Cell
PT3265555T (pt) Expansão de células t
GB201603372D0 (en) Cell
ZA201900891B (en) B-cell-mimetic cells
GB201609604D0 (en) Cell
GB201617716D0 (en) Cell
ZA201800972B (en) Methanogenesis
HUE042287T2 (hu) Lítium-kén cella
SG10201403640XA (en) Stem cells
GB201402787D0 (en) Expansion method
GB201604427D0 (en) Modified cell
GB201402786D0 (en) Expansion method
GB201421717D0 (en) Cell expansion procedure
GB201507816D0 (en) Cell
GB201507819D0 (en) Cell
GB201507814D0 (en) Cell

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)